U.S. Patent No. 10,874,687 B1 (‘687), issued on December 29, 2020, to inventors Jean-Pierre Sommadossi of Boston, Massachusetts, and Adel Moussa of Burlington, Massachusetts. The applicant/assignee is Atea Pharmaceuticals, Inc. of Boston, Massachusetts, an anti-viral drug developer.
The claims are directed to a method of therapeutic use for treating COVID-19, comprising the purine nucleotide phosphoramidate compounds.
The following shows the Compound 1 as claimed in Claim 1.
Source: U.S. Patent No. 10,874,687 B1, Dec. 29, 2020, Jean-Pierre Sommadossi and Adel Moussa (inventors); Atea Pharmaceuticals, Inc. (applicant/assignee)
The Cooperative Patent Classifications include A61K, preparations for medical, dental or toilet purposes, namely, carbohydrates, sugars or derivatives containing purines, e.g., adenosine or adenylic acid (31/7076), medicinal preparations characterized by special physical form, namely, injectable compositions, intermscular, intravenous, arterial or subcutaneous administration (9/0019), and through mouth and digestive tract, i.e., intraoral and peroral administration (9/0053), and solutions (9/08); and A61P, specific therapeutic activity of chemical compounds or medicinal preparations, namely, antiinfectives, i.e., antibiotics, antispetics, and antivirals for RNA viruses (31/14).
For more information on this patent, or the patent process, please contact Yonaxis IP.